MedTrace Logo

A Study of Regadenoson in Subjects Undergoing Stress Myocardial Perfusion Imaging (MPI) Using Multidetector Computed Tomography (MDCT) Compared to Single Photon Emission Computed Tomography (SPECT)

NCT01334918 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 124

Last updated 2024-12-04

Study results available
· View outcomes & findings →

Summary

The purpose of this study is to compare Multidetector Computed Tomography (MDCT) and Single Photon Emission Computed Tomography (SPECT) stress myocardial perfusion imaging (MPI) with regadenoson in order to detect the presence or absence of reversible defects.

Conditions

  • Coronary Artery Disease (CAD)

Interventions

DRUG

regadenoson

Administered by intravenous bolus.

RADIATION

technetium Tc99m sestamibi /technetium Tc99m tetrafosmin

Administered by intravenous infusion

RADIATION

Contrast

Administered by intravenous infusion.

PROCEDURE

Single Photon Emission Computed Tomography

Procedure/Surgery

PROCEDURE

Multidetector Computed Tomography

Procedure/Surgery

Sponsors & Collaborators

  • Astellas Pharma Inc

    lead INDUSTRY

Principal Investigators

  • Senior Medical Director · Astellas Pharma Global Development

Study Design

Allocation
RANDOMIZED
Purpose
DIAGNOSTIC
Masking
NONE
Model
CROSSOVER

Eligibility

Min Age
45 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2011-04-26
Primary Completion
2012-07-02
Completion
2012-07-02

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01334918 on ClinicalTrials.gov